Advanced Quantitative Imaging Program Using NeuroQuant® and OnQ Prostate/®
Advanced imaging is most powerful when it delivers objective, reproducible insight—not just visual interpretation. Our Advanced Quantitative Imaging Program integrates NeuroQuant® and OnQ Prostate® to provide AI-assisted, quantitative analysis for brain and prostate MRI.
Supporting earlier detection, clearer characterization, and more confident clinical decisions.
Physician-Led AI Intelligence
AI insights directed by experienced physicians throughout your care.
Premium Concierge
Private suites, personalized care, and dedicated support throughout your visit.
Latest Technology
Research-Grade MRI, CT, and PET/CT imaging systems for superior diagnostic accuracy.
Prime Manhattan Location
Conveniently located in the heart of Manhattan with easy access and nearby parking.
AI-Assisted Analysis
FDA-cleared quantitative platforms
Objective Measurements
Reproducible, standardized results
Longitudinal Tracking
Monitor changes over time
Non-Invasive
Standard MRI data analysis
Moving Beyond Visual Interpretation
Traditional MRI interpretation relies heavily on visual assessment and qualitative judgment. While effective, subtle changes in tissue volume, structure, or tumor characteristics may be difficult to detect early or track consistently over time.
NeuroQuant® and OnQ Prostate® apply advanced, FDA-cleared quantitative analysis to MRI data—transforming images into measurable, standardized insights that support objective evaluation and clearer communication between radiologists, referring physicians, and patients.
This program is designed to complement standard radiologic interpretation with precise measurements that enhance diagnostic confidence.
What This Program Adds to MRI
Objective, quantitative measurements
Standardized outputs for consistency
AI-assisted physician workflows
Structured reports for care planning
Two Powerful AI Platforms, One Program
NeuroQuant®
Automated brain segmentation and volumetric analysis designed to support assessment of neurodegenerative and neurological conditions. Compares patient-specific brain volumes against age- and sex-matched normative databases.
NeuroQuant® Supports:
- Objective assessment of brain structure volumes
- Early identification of neurodegeneration patterns
- Longitudinal tracking of disease progression
- Improved consistency and inter-reader agreement
OnQ Prostate®
FDA-cleared advanced MRI analysis designed to enhance detection, localization, and characterization of clinically significant prostate cancer using Restriction Spectrum Imaging (RSI) and AI-assisted analysis.
OnQ Prostate® Supports:
- Objective assessment of brain structure volumes
- Early identification of neurodegeneration patterns
- Longitudinal tracking of disease progression
- Improved consistency and inter-reader agreement
A More Personalized Imaging-Driven Care Pathway
Every patient's disease process is unique. Quantitative imaging enables a more individualized approach by providing objective metrics that can be tracked over time.
By integrating NeuroQuant® and OnQ Prostate® into a single advanced imaging program, physicians can:
- Detect subtle changes earlier than visual interpretation alone
- Monitor progression or stability with greater confidence
- Support shared decision-making with clearer data
- Align imaging findings more closely with clinical context
Tailored & Thoughtful
This enables a more tailored, thoughtful pathway—focused on clarity rather than assumption.
How the Program Works
MRI Acquisition
High-resolution brain or prostate MRI is performed using advanced scanners.
AI-Assisted Quantitative Analysis
Imaging data is processed using NeuroQuant® or OnQ Prostate® platforms..
Objective Measurement & Characterization
Volumes, lesion characteristics, and structural metrics are quantified.
Physician Review
Results are reviewed within clinical context alongside patient history.
Clear Results Delivery
Findings are presented in structured, easy-to-interpret reports.
Designed for Patients and Referring Physicians
HeartFlow Coronary CTA provides value for both patients seeking clarity and physicians guiding care decisions.
For Patients
- Undergoing evaluation for memory, cognitive, or neurological concerns
- Require baseline or follow-up assessment of neurodegenerative conditions
- Being evaluated for suspected or known prostate cancer
- Need improved lesion localization for biopsy or treatment planning
- Prefer advanced, data-driven insight alongside standard imaging
For Referring Physicians
- Consistent, quantitative outputs that support confidence
- Standardized data for longitudinal comparison
- Supports informed decision-making and care planning
- Enhanced communication with patients
- Continuity of care through reproducible metrics
Physician-Led Quantitative Imaging Program
NeuroQuant® and OnQ Prostate® are offered as part of a physician-guided imaging program focused on responsible use, clinical relevance, and clear communication. This ensures advanced analytics enhance care without replacing clinical judgment.
Advanced Imaging Quality
Reproducible Measurements
Thoughtful Interpretation
Clear Results Presentation
Choose Your Quantitative MRI
MRI NEURO with Neuroquant
$650
Advanced brain MRI with AI-powered volumetric analysis to assess brain health, cognitive function, and age-related changes.
MRI NEURO with Neuroquant MS
$650
Specialized brain volume analysis optimized for multiple sclerosis monitoring and tracking disease progression.
AI Prostate MRI Package (OnQ Prostate)
$3,000
All-inclusive prostate MRI package with AI-enhanced analysis, color fusion maps, and a detailed radiologist report you can share with your urologist.
Frequently Asked Questions
These platforms provide quantitative analysis to support clinical decision-making. Diagnosis and treatment decisions remain the responsibility of the treating physician.
No. Both analyses are performed using standard, non-invasive MRI data
Results are reviewed within a physician-guided clinical framework as part of the overall imaging interpretation
Yes. Quantitative outputs support longitudinal comparison and monitoring when clinically appropriate.